The biomarkes NT-proBNP, ST2 and Pentraxin-3 (Ptx-3) have emerged as potential powerful tools

worldwide. In addition to the classic biomarker NT-proBNP, new biomarkers like ST2 and Pentraxin-3 (Ptx-3

-discharge mortality of patients with COVID-19 pneumonia. Methods: Serum soluble ST2, VCAM-1, and hs-TnI were

.04 (0.76), P < 0.001]. While both treatment groups displayed a reduced rate of CVM [DOAC: B = −2.69 (0

randomized for RIPC (n=26, 60.5±2.0 years) or sRIPC (n=25, 62.96±1.7). RIPC was performed before the CAG

and sensitive biomarkers such as ST2 and Pentraxin-3 (Ptx-3) have prediction potential in HF and primary

. The patients were randomized for RIPC (n = 26, 60.5 ± 2.0 years) or 12 sRIPC (n = 25, 62.96 ± 1.7). RIPC

with CHD and CKD and creatinine clearance <80 ml/min/m2 expecting coronaroangiography were investigated

and processes responsible for arrhythmogenesis remains incomplete. Given the crucial role of Ca2+-handling